Cancer-induced expansion and activation of CD11b+ Gr-1+ cells predispose mice to adenoviral-triggered anaphylactoid-type reactions.

[1]  王林,et al.  American Academy of Allergy，Asthma and Immunology , 2010 .

[2]  D. Carbone,et al.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. , 2008, Cancer cell.

[3]  F. Peale,et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.

[4]  F. Finkelman.  Anaphylaxis: lessons from mouse models. , 2007, The Journal of allergy and clinical immunology.

[5]  Paolo Serafini,et al.  Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. , 2006, The Journal of clinical investigation.

[6]  Sheryl G. A. Gabram,et al.  Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial , 2006, Annals of Surgical Oncology.

[7]  W. Studer,et al.  Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: case report and review of the nomenclature of vital blue dyes. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[9]  C. Tournigand,et al.  Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. , 2005, European journal of cancer.

[10]  H. Engler,et al.  Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  P. Sinha,et al.  Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression , 2005, Cancer Immunology, Immunotherapy.

[12]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[13]  Joint Task Force on Practice Parameters.  The diagnosis and management of anaphylaxis: an updated practice parameter. , 2005, The Journal of allergy and clinical immunology.

[14]  R. Nicklas.  The diagnosis and management of anaphylaxis , 2005 .

[15]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[16]  Jie Tian,et al.  Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  P. Sinha,et al.  Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease , 2004, Cancer Research.

[18]  J. Berzofsky,et al.  Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance , 2003, The Journal of Experimental Medicine.

[19]  S. Kochanek,et al.  A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. , 2003, Human gene therapy.

[20]  W. Hiddemann,et al.  Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution , 2003, Anti-cancer drugs.

[21]  R. Warren,et al.  Intravascular adenoviral agents in cancer patients: Lessons from clinical trials , 2002, Cancer Gene Therapy.

[22]  D. Gabrilovich,et al.  Immature myeloid cells and cancer-associated immune suppression , 2002, Cancer Immunology, Immunotherapy.

[23]  F. Finkelman,et al.  Pathways of anaphylaxis in the mouse. , 2002, The Journal of allergy and clinical immunology.

[24]  J. MacDonald,et al.  Porcine Toxicology Studies of SCH 58500, an Adenoviral Vector for the p53 Gene , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[25]  David Fear,et al.  The biology of IGE and the basis of allergic disease. , 2001, Annual review of immunology.

[26]  S. Singletary,et al.  Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. , 2001, American journal of surgery.

[27]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[28]  M. Caligiuri,et al.  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. , 1999, Journal of immunology.

[29]  P. Elson,et al.  Clinical features of hypersensitivity reactions to carboplatin. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Mullins,et al.  Tumor‐induced immune dysfunction: the macrophage connection , 1998, Journal of leukocyte biology.

[31]  M. Kay,et al.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors , 1997, Journal of virology.

[32]  C. Scandella,et al.  Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. , 1995, Human gene therapy.

[33]  N. Van Rooijen,et al.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. , 1994, Journal of immunological methods.

[34]  F. Miller,et al.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.

[35]  M. Castells.  Rapid desensitization of hypersensitivity reactions to chemotherapy agents. , 2006, Current drug safety.